GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins
Robert J. Watson, Paul Bamborough, Heather Barnett, Chun‐wa Chung, Rob P. Davis, Laurie Gordon, Paola Grandi, M. Petretich, Alex Phillipou, Rab K. Prinjha, Inmaculada Rioja, Peter E. Soden, Thilo Werner, Emmanuel H. Demont
Abstract
Pan-bromodomain and extra terminal (BET) inhibitors interact equipotently with all eight bromodomains of the BET family of proteins. They have shown profound efficacy in vitro and in vivo in oncology and immunomodulatory models, and a number of them are currently in clinical trials where significant safety signals have been reported. It is therefore important to understand the functional contribution of each bromodomain to assess the opportunity to tease apart efficacy and toxicity. This article discloses the in vitro and cellular activity profiles of GSK789, a potent, cell-permeable, and highly selective inhibitor of the first bromodomains of the BET family.